Biotechnology (642) | Note Agreements (642)

Browse by Company

Adhera Therapeutics, Inc. (17 contracts)
ADiTx Therapeutics, Inc. (11)
ADURO BIOTECH, INC. (3)
AGENUS INC (1)
AgeX Therapeutics, Inc. (5)
Allarity Therapeutics, Inc. (1)
Alliqua BioMedical, Inc. (2)
Alpha Healthcare Acquisition Corp. (1)
Alzamend Neuro, Inc. (1)
AMARILLO BIOSCIENCES INC (11)
Amgen Inc. (7)
AMICUS THERAPEUTICS, INC. (4)
Amplitude Healthcare Acquisition Corp (1)
AquaBounty Technologies, Inc. (1)
Aridis Pharmaceuticals, Inc. (2)
Artiva Biotherapeutics, Inc. (1)
ARYA Sciences Acquisition Corp II (1)
Avid Bioservices, Inc. (1)
Axcella Health Inc. (1)
AZIYO BIOLOGICS, INC. (3)
AzurRx BioPharma, Inc. (3)
Big Cypress Acquisition Corp. (1)
bioAffinity Technologies, Inc. (8)
BioAtla, Inc. (1)
BioCardia, Inc. (2)
Biogen Inc. (3)
BioLife4D Corp (15)
BioRestorative Therapies, Inc. (9)
Biostage, Inc. (1)
BIOTIME INC (1)
BIOXYTRAN, INC (13)
Bone Biologics Corp (8)
BullFrog AI Holdings, Inc. (2)
Calyxt, Inc. (2)
CANCER GENETICS, INC (3)
CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (5)
Caribou Biosciences, Inc. (1)
CASI Pharmaceuticals, Inc. (1)
Castle Creek Biosciences, Inc. (1)
Cell Source, Inc. (8)
Celsion CORP (1)
Centessa Pharmaceuticals Ltd (1)
CEREBAIN BIOTECH CORP. (3)
Chanticleer Holdings, Inc. (1)
Chardan Healthcare Acquisition 2 Corp. (2)
Chardan Healthcare Acquisition Corp. (1)
Chelsea Worldwide Inc. (3)
CHIMERIX INC (1)
CLEVELAND BIOLABS INC (4)
CM Life Sciences III Inc. (1)
Coherus BioSciences, Inc. (1)
Consonance-HFW Acquisition Corp. (1)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (5)
CTD HOLDINGS INC (1)
Curative Biotechnology Inc (15)
CytoDyn Inc. (7)
Digital Development Partners, Inc. (14)
Dynamics Special Purpose Corp. (4)
ENDONOVO THERAPEUTICS, INC. (1)
Enochian Biosciences Inc (5)
Entasis Therapeutics Holdings Inc. (1)
Environmental Impact Acquisition Corp (1)
FS Development Corp. (1)
FS Development Corp. II (2)
GALECTIN THERAPEUTICS INC (4)
Gamida Cell Ltd. (1)
GENELUX CORP (2)
GENEREX BIOTECHNOLOGY CORP (7)
GeoVax Labs, Inc. (1)
Greater Cannabis Company, Inc. (8)
GT Biopharma, Inc. (18)
GX Acquisition Corp. (1)
HALOZYME THERAPEUTICS INC (2)
HARBOR DIVERSIFIED, INC. (2)
Health Sciences Acquisitions Corp (1)
HedgePath Pharmaceuticals, Inc. (1)
HEMISPHERX BIOPHARMA INC (5)
HERON THERAPEUTICS, INC. (1)
HilleVax, Inc. (1)
Hillstream BioPharma Inc. (2)
HISTOGENICS CORP (3)
HUMANIGEN, INC (7)
iBio, Inc. (2)
IDERA PHARMACEUTICALS, INC. (1)
Immix Biopharma, Inc. (1)
IMMUCELL CORP (1)
Immune Therapeutics, Inc. (16)
ImmunoCellular Therapeutics, Ltd. (1)
IMPEL NEUROPHARMA INC (1)
Inhibikase Therapeutics, Inc. (6)
Inhibrx, Inc. (3)
International Stem Cell CORP (11)
INTREXON CORP (1)
Intrinsic Medicine, Inc. (1)
Invitae Corp (2)
IONIS PHARMACEUTICALS INC (1)
IRONWOOD PHARMACEUTICALS INC (4)
Isoray, Inc. (1)
KBL MERGER CORP. IV (10)
Kiromic Biopharma, Inc. (9)
KIWA BIO-TECH PRODUCTS GROUP CORP (5)
Leisure Acquisition Corp. (14)
LifeSci Acquisition Corp. (1)
Locust Walk Acquisition Corp. (2)
LONGEVERON LLC (1)
MANNKIND CORP (5)
MARIZYME INC (8)
MATEON THERAPEUTICS INC (21)
Medovex Corp. (16)
MiNK Therapeutics, Inc. (3)
MIRAGEN THERAPEUTICS, INC. (1)
NANOVIRICIDES, INC. (1)
NantKwest, Inc. (16)
NAVIDEA BIOPHARMACEUTICALS, INC. (1)
NexImmune, Inc. (1)
NORTHWEST BIOTHERAPEUTICS INC (1)
NTN BUZZTIME INC (4)
Nuo Therapeutics, Inc. (12)
Ohr Pharmaceutical Inc (2)
OncBioMune Pharmaceuticals, Inc (11)
OncoCyte Corp (1)
ONCOSEC MEDICAL Inc (1)
OPGEN INC (3)
Opko Health, Inc. (1)
Organicell Regenerative Medicine, Inc. (2)
Orgenesis Inc. (4)
Outlook Therapeutics, Inc. (9)
Petra Acquisition Inc. (5)
POLARITYTE, INC. (1)
PRECISION BIOSCIENCES INC (2)
PREDICTIVE TECHNOLOGY GROUP, INC. (1)
PREMIER BIOMEDICAL INC (1)
PROGENITY, INC. (2)
Propanc Biopharma, Inc. (28)
Protagenic Therapeutics, Inc. (3)
PROTEOSTASIS THERAPEUTICS, INC. (1)
PUMA BIOTECHNOLOGY, INC. (4)
Q BioMed Inc. (1)
Qrons Inc. (5)
Rasna Therapeutics Inc. (1)
REGENERX BIOPHARMACEUTICALS INC (4)
RenovoRx, Inc. (3)
REXAHN PHARMACEUTICALS, INC. (3)
Rich Pharmaceuticals, Inc. (2)
Shuttle Pharmaceuticals Holdings, Inc. (21)
Social Capital Suvretta Holdings Corp. III (2)
Sorrento Therapeutics, Inc. (1)
SPHERIX INC (1)
Spinning Eagle Acquisition Corp. (1)
Summit Therapeutics Inc. (6)
TENAX THERAPEUTICS, INC. (1)
USA EQUITIES CORP. (6)
VACCINEX, INC. (1)
VITRO DIAGNOSTICS INC (7)
WINDTREE THERAPEUTICS INC (1)
YIELD10 BIOSCIENCE, INC. (1)

Recent Contracts

Senior Unsecured Promissory Note issued by Nexcella, Inc. to Immix Biopharma, Inc. on December 21, 2022 (Immix Biopharma, Inc., Filed With SEC on March 27, 2023)
Form of Note issued on March 15, 2023 (International Stem Cell CORP, Filed With SEC on March 16, 2023)
Convertible Promissory Note, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (AgeX Therapeutics, Inc., Filed With SEC on March 15, 2023)
Convertible Note Purchase Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (AgeX Therapeutics, Inc., Filed With SEC on March 15, 2023)
Secured Convertible Promissory Note dated March 13, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (AgeX Therapeutics, Inc., Filed With SEC on March 15, 2023)
CONVERTIBLE NOTE PURCHASE AGREEMENT (AMARILLO BIOSCIENCES INC, Filed With SEC on March 14, 2023)
CONVERTIBLE NOTE PURCHASE AGREEMENT (AMARILLO BIOSCIENCES INC, Filed With SEC on March 14, 2023)
Series B Global Note representing the Series B 4.50% Convertible Senior Secured Notes due 2028 (Invitae Corp, Filed With SEC on March 8, 2023)
Series A Global Note representing the Series A 4.50% Convertible Senior Secured Notes due 2028 (Invitae Corp, Filed With SEC on March 8, 2023)
Promissory Note made in favor of AJB Capital Investments dated March 6, 2023 (Organicell Regenerative Medicine, Inc., Filed With SEC on March 8, 2023)
Form of Original Issue Discount Senior Secured Promissory Note (Adhera Therapeutics, Inc., Filed With SEC on March 8, 2023)
Officers Certificate of the Company, dated as of March 2, 2023, including forms of the Companys 5.250% Senior Notes due 2025, 5.507% Senior Notes due 2026, 5.150% Senior Notes due... (Amgen Inc., Filed With SEC on March 2, 2023)
Form of Convertible Promissory Note (Medovex Corp., Filed With SEC on March 2, 2023)
Fourth Amendment to Note Purchase Agreement, dated November29, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (PUMA BIOTECHNOLOGY, INC., Filed With SEC on March 2, 2023)
Second Amendment to Note Purchase Agreement, dated May 18, 2022,by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (PUMA BIOTECHNOLOGY, INC., Filed With SEC on March 2, 2023)
Form of Amended 5% Convertible Promissory Note dated February 10, 2023 (Opko Health, Inc., Filed With SEC on February 27, 2023)
Form of the 25% Senior Secured Convertible Promissory Note (Kiromic Biopharma, Inc., Filed With SEC on February 27, 2023)
Amendment No.2 to Promissory Note, dated May 17, 2022 (Enochian Biosciences Inc, Filed With SEC on February 27, 2023)
Form of Original Issue Discount Senior Secured Promissory Note (Adhera Therapeutics, Inc., Filed With SEC on February 23, 2023)
Form of the Convertible Senior Secured Promissory Note (CAPSTAR SPECIAL PURPOSE ACQUISITION CORP., Filed With SEC on February 23, 2023)
Note Purchase Agreement, dated February 21, 2023, by and among Gelesis Holdings, Inc., Gelesis, Inc., Gelesis 2012, Inc., Gelesis LLC and PureTech Health LLC (CAPSTAR SPECIAL PURPOSE ACQUISITION CORP., Filed With SEC on February 23, 2023)
Amendment to Promissory Note (Enochian Biosciences Inc, Filed With SEC on February 23, 2023)
Form of Amended and Restated Senior Secured Convertible Promissory Note (Enochian Biosciences Inc, Filed With SEC on February 23, 2023)
10% Convertible Redeemable Note, dated February 14, 2023, issued by the Company to ONE44 Capital LLC (Propanc Biopharma, Inc., Filed With SEC on February 21, 2023)
Amendment No. 1 to Promissory Note and Pledge Agreement, dated March 24, 2022, by and between Rory Riggs and Cibus Global, LLC (Calyxt, Inc., Filed With SEC on February 14, 2023)
Promissory Note and Pledge Agreement, dated December 31, 2020, in the original principal amount of $4,065,845.44, by and between Rory Riggs and Cibus Global, LLC (Calyxt, Inc., Filed With SEC on February 14, 2023)
Amendment, dated February 10, 2023, to the Convertible Promissory Note, dated December 22, 2022, by and between the Company and Streeterville Capital, LLC (Outlook Therapeutics, Inc., Filed With SEC on February 14, 2023)
Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (AgeX Therapeutics, Inc., Filed With SEC on February 10, 2023)
Promissory Note dated January 11, 2023, in favor of 1800 Diagonal Lending LLC (Digital Development Partners, Inc., Filed With SEC on February 7, 2023)
Convertible Promissory Note dated August 18, 2022, in favor of Boot Capital, LLC (Digital Development Partners, Inc., Filed With SEC on February 7, 2023)
Unsecured Subordinated Convertible Promissory Note issued by Marizyme, Inc., dated February 6, 2023 (MARIZYME INC, Filed With SEC on February 7, 2023)
Form of Idera Pharmaceuticals, Inc. Convertible Unsecured Promissory Notes (IDERA PHARMACEUTICALS, INC., Filed With SEC on February 3, 2023)
Promissory Note issued by Marizyme, Inc. to Hexin Global Ltd., dated December 28, 2022 (MARIZYME INC, Filed With SEC on February 1, 2023)
Form of 8% Convertible Promissory Note (VITRO DIAGNOSTICS INC, Filed With SEC on January 30, 2023)
Form of Original Issue Discount Senior Secured Promissory Note (Adhera Therapeutics, Inc., Filed With SEC on January 26, 2023)
Form of the 25% Senior Secured Convertible Promissory Note (Kiromic Biopharma, Inc., Filed With SEC on January 26, 2023)
Form of Note Purchase Agreement (Kiromic Biopharma, Inc., Filed With SEC on January 26, 2023)
Seventh Amendment to March 2022 Convertible Note Transaction Documents (Curative Biotechnology Inc, Filed With SEC on January 25, 2023)
Convertible Loans and Unsecured Convertible Notes Extension #2 Agreement, dated as of January 12, 2023, by and between the Company and Yehuda Nir (Orgenesis Inc., Filed With SEC on January 18, 2023)
Seventh Amendment to March 2022 Convertible Note Transaction Documents (Curative Biotechnology Inc, Filed With SEC on January 13, 2023)